KALA BIO, Inc. — Director's Dealing 2018

Apr 9, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2018-04-05

Reporting Person: Trachtenberg Eric (General Counsel and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-05	Stock Option (right to buy)	$16.62	A	150000	Acquired	2028-04-04	Common Stock (150000)	Direct

Footnotes

F1: This option was granted on April 5, 2018 and vests over four years beginning on the vesting commencement date of April 2, 2018, with 25% of the shares underlying the option vesting on April 2, 2019, and an additional 2.0833% of the shares underlying the option vesting at the end of each successive one-month period thereafter.